GCG and obesity disorder: Several other peptidomimetics, including multitargeted molecules—dual and triple agonists targeting GLP-1, glucagon and gastric inhibitory polypeptide receptors—are in clinical trials as possible future anti-obesity drugs (Williams, Nawaz, and Evans 2020).